Lucid-MS is a patented neuroprotective compound that has demonstrated in preclinical models to prevent and reverse myelin degradation, a cause for Multiple Sclerosis, as well as other neurodegenerative diseases and conditions. Lucid-MS has shown excellent results in several animal models, as demonstrated in the video below.

The subject in the video above is only one example taken from a large cohort of mice in experiments conducted in multiple labs across several years. The results of the preclinical research from these experiments has been published in various prestigous medical journals, including Journal of Medicinal Chemistry and Proceedings of the National Academy of Sciences (PNAS). Lucid-MS is a patented ((patent #WO2017027967A1) New Chemical Entity (NCE) that has been studied extensively throughout more than 11 years of research and development. FSD Pharma owns exclusive worldwide rights to Lucid-MS.

A sampling of the novel qualities of Lucid-MS include:

• Excellent efficacy in various preclinical animal models
• Accelerates functional recovery of mouse models of Multiple Sclerosis, preserves myelin, and reduces zonal degredation
• Does not suppress immune system (non-immunomodulatory)
• Potential oral administration with easy dosing regimen

In Q1 2023, FSD Pharma received approval from Health Canada in the form of a “No Objection Letter” to proceed with a proposed Phase 1 clinical trial that will evaluate the safety and tolerability of Lucid-MS as a new drug candidate for the treatment of Multiple Sclerosis.

Armed with a strong balance sheet, solid pipeline, and renowned clinical team, FSD intends to advance its lead drug candidates through clinical trials with the goal of providing therapies to the millions suffering from neurodegenerative and neuropsychiatric conditions.